Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 …

13 hours ago · Novo Nordisk accounts for 34% of the global diabetes market, including roughly half of both the $15 billion insulin therapy market and the $40 billion GLP-1 market. Novo …

CouponFollow Extension

34%
OFF

Novo Nordisk's Innovation Supports A Wide Moat And GLP-1 …

3 weeks from now

13 hours ago · Novo Nordisk accounts for 34% of the global diabetes market, including roughly half of both the $15 billion insulin therapy market and the $40 billion GLP-1 market. Novo …

morningstar.com

24%
OFF

Novo Nordisk: GLP-1 Leadership Redefining Chronic Care—Will …

3 weeks from now

Novo Nordisk delivered strong Q3 2024 results, with year-to-date sales and operating profit growth of 24% and 22%, respectively, driven by the continued success of GLP-1 drugs …

equisights.com

$3
OFF

Sales Balloon For GLP-1 Drugs From Novo Nordisk, Eli Lilly

3 weeks from now

Nov 7, 2024 · Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity. Novo’s GLP-1 drug, …

bioworld.com

2%
OFF

Why Is Novo Outperforming Lilly Despite Having Inferior GLP-1 …

3 weeks from now

Jan 3, 2025 · Novo itself entered the weight management space in 2014 with Saxenda, a GLP-1 drug that led to an average loss of 9.2% of initial body weight. In other words, the success of …

biospace.com

24%
OFF

Novo Nordisk: New GLP-1 Drug Shows Leading Weight

3 weeks from now

Jan 27, 2025 · Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a phase 1b/2a study in patients with obesity or …

morningstar.co.uk

$200
OFF

Can New GLP-1 Contenders Disrupt The Weight-Loss Giants, Lilly …

3 weeks from now

Oct 3, 2024 · N ew public and private entrants are emerging to challenge the leading positions of Novo Nordisk (NVO) and Eli Lilly (LLY) in the GLP-1 market.This potential $200 billion market …

geneonline.com

30%
OFF

Novo Nordisk Earnings: Raising Fair Value On Improving GLP-1 …

3 weeks from now

1 day ago · Economic Moat Capital Allocation ... with Novo Nordisk seeing 30% GLP-1 growth. We still see a more than $200 billion GLP-1 market by 2031. ... Novo Nordisk's Innovation …

morningstar.com

$50
OFF

Novo Nordisk: Next-Generation GLP-1/Amylin Drug Sees

3 weeks from now

Jan 24, 2025 · Novo and Lilly are fighting for share in a global GLP-1 market that surpassed $50 billion in 2024 and is likely to reach $200 billion by 2031, as supply and insurance coverage …

morningstar.com

FAQs about Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 … Coupon?

Does Novo Nordisk have a GLP-1 lab?

In addition, Novo plans to expand the Chartres site’s current quality control laboratory. The outlay is designed to boost Novo Nordisk’s ability to meet future demands for its drugs, including GLP-1 products, the company explained. ...

Who will challenge Novo Nordisk & Eli Lilly in the GLP-1 market?

New public and private entrants are emerging to challenge the leading positions of Novo Nordisk (NVO) and Eli Lilly (LLY) in the GLP-1 market. This potential $200 billion market is projected to see 68% of sales from weight loss indications by 2031. Initially approved for diabetes, GLP-1 drugs are now gaining new indications, including obesity. ...

Is Novo Nordisk launching a 'next generation' weight-loss drug?

Novo Nordisk is the most valuable company in Europe Pharma giant Novo Nordisk is working on its ‘next generation’ weight-loss drug, CagriSema, which it believes will pioneer GLP-1 treatments. Glucagon-like peptide-1 (GLP-1) is a hormone which plays a vital role in glucose metabolism and appetite regulation. ...

Are Lilly & Novo Nordisk launching a GLP-1 drug?

But while Lilly and Novo Nordisk have built up a good headstart when it comes to the obesity space, competition is on the horizon. Several companies are working on GLP-1 drugs, such as Amgen, which touted encouraging interim clinical data for its drug MariTide in its earnings call earlier this month. ...

What is Novo Nordisk doing with metaphore?

Last week, Novo Nordisk announced it had entered into a research agreement with biotech company Metaphore to develop two new therapeutics in a deal potentially worth up to $600 million. That’s in addition to its new GLP-1 treatment CagriSema, a combination of GLP-1 drug and a second drug geared towards diabetes and weight loss. ...

Is Novo Nordisk a good company?

For over a century, Danish pharma Novo Nordisk has been working to prevent and cure chronic diseases. Now, it is the most valuable company in Europe. Novo Nordisk’s treatments benefit millions of people who live with diabetes or obesity, as well as those with rare blood and endocrine diseases. ...